APLS Company Profile and Key Details
NASDAQ : APLS
Apellis Pharmaceuticals
$40.88
-0.025-0.06%
Open: 9:39 AM70.23
BESG ScoreESG Rating
Price Chart
Stock Price Today
Apellis Pharmaceuticals, Inc. (APLS) stock declined over -0.06%, trading at $40.88 on NASDAQ, down from the previous close of $40.90. The stock opened at $40.88, fluctuating between $40.88 and $40.90 in the recent session.
Stock Snapshot
40.9
Prev. Close
5.23B
Market Cap
40.875
Day Low
227.08
P/E Ratio
0.18
EPS (TTM)
-4.91
Cash Flow per Share
40.88
Open
127.83M
Number of Shares
40.9
Day High
82.62%
Free Float in %
1.6
Book Value
173.19K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 17, 2026 | 40.86 | 40.95 | 40.85 | 40.90 | 5.22M |
| Apr 16, 2026 | 40.84 | 40.90 | 40.80 | 40.87 | 6.29M |
| Apr 14, 2026 | 40.85 | 40.88 | 40.78 | 40.85 | 4.52M |
| Apr 13, 2026 | 40.73 | 40.87 | 40.70 | 40.84 | 5.83M |
| Apr 10, 2026 | 40.67 | 40.79 | 40.65 | 40.79 | 6.74M |
| Apr 09, 2026 | 40.74 | 40.76 | 40.64 | 40.65 | 7.06M |
| Apr 08, 2026 | 40.66 | 40.74 | 40.65 | 40.69 | 4.58M |
| Apr 07, 2026 | 40.61 | 40.77 | 40.60 | 40.70 | 4.3M |
| Apr 06, 2026 | 40.43 | 40.69 | 40.41 | 40.63 | 6.08M |
| Apr 02, 2026 | 40.37 | 40.48 | 40.35 | 40.41 | 10.33M |
| Apr 01, 2026 | 40.35 | 40.42 | 40.32 | 40.39 | 28.76M |
| Mar 31, 2026 | 40.40 | 40.45 | 40.22 | 40.23 | 90.33M |
| Mar 30, 2026 | 16.98 | 17.27 | 16.83 | 17.09 | 2.16M |
| Mar 27, 2026 | 17.55 | 17.61 | 16.97 | 16.97 | 1.76M |
| Mar 25, 2026 | 17.44 | 17.96 | 17.39 | 17.72 | 1.87M |
| Mar 24, 2026 | 17.46 | 17.46 | 16.84 | 17.23 | 2.14M |
| Mar 23, 2026 | 17.60 | 17.94 | 17.32 | 17.57 | 2.41M |
| Mar 20, 2026 | 17.96 | 18.09 | 17.16 | 17.21 | 5.6M |
| Mar 19, 2026 | 17.89 | 18.01 | 17.57 | 17.97 | 2.33M |
| Mar 18, 2026 | 18.43 | 18.59 | 17.43 | 17.89 | 5.25M |
Contact Details
About Company
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Company Information
| Employees | 705 |
| Beta | 0.29 |
| Sales or Revenue | $396.59M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
20.69+2.50%
argenx SE$849.04REGN4.57+0.61%
Regeneron Pharmaceuticals, Inc.$750.57UTHR7.87+1.36%
United Therapeutics Corporation$588.38MDGL7.26+1.38%
Madrigal Pharmaceuticals, Inc.$532.02VRTX5.55+1.27%
Vertex Pharmaceuticals Incorporated$441.20PRAX22.11+6.90%
Praxis Precision Medicines, Inc.$342.50KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-10.47-3.27%
Alnylam Pharmaceuticals, Inc.$309.66KRYS10.15+3.84%
Krystal Biotech, Inc.$274.21ASND1.53+0.63%
Ascendis Pharma A/S$244.48Company Overview
The stock is currently trading near its 52-week high $16.10 and $40.95. With a market capitalization of about $5.23 billion, Apellis Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.20). Key stats such as the average daily volume over the past year has been around 5.16 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Apellis Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Cedric Francois, the company employs approximately 705 people and listed since November 09, 2017. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
Technical Performance
APLS has shown weak momentum, losing -11.77% over the past week and -16.52% over the past quarter, though year-to-date performance is down -18.51%. Short-term trend indicators are mixed aligned (SMA20 -3.6%, SMA50 -6.81%, SMA200 -3.13%). The stock’s 14-day RSI is 44.0 (neutral), while the ATR of 1.2 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.0% below its high and over 34.41% above its low. Average 10-day trading volume of 5.72 million shares is in line with the 3-month average of 5.20 million, indicating normal recent market interest.
Valuation Metrics
Apellis Pharmaceuticals, Inc. trades at a P/E ratio of 230.23, slightly above the S&P 500 average, with a price-to-sales ratio of 5.21 and a price-to-book ratio of 13.93 reflecting a rich premium to book value. The P/FCF stands at 115.35, also above market averages. Compared to sector medians, Apellis Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
Apellis Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$34.58. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Wall Street analysts project EPS growth of 61.57% annually over the next five years. The latest quarter delivered EPS of $1.67. The next quarter is forecast at -$0.35. Next year's EPS is expected at $61.45. Analyst sentiment is bullish. Analyst rating data shows there are 11 Strong Buy ratings, 13 Buy ratings, 14 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $18.00. The high target offers 34.47% upside. The low target suggests -55.99% downside. The mean target is $35.95. This offers -12.1% upside. Apellis Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by 62.14%.
Shareholding & Insider Activity
Apellis Pharmaceuticals, Inc. has 127.84 million shares outstanding. The public float is 83.25 million shares, elevated short interest at 23.54% of float. This equals 22.93 million shares. The short ratio is 11.43 days. Institutional investors hold 120.35% of the float. Insiders own 13.64%. Deschatelets Pascal holds 1.15 million shares, Machiels Alec has 367.42 thousand shares and Francois Cedric has 286.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 138.56 thousand shares across 28 transactions.
Financial & Profitability Overview
On valuation metrics, Apellis Pharmaceuticals trades at a P/E of 230.23, P/S of 5.21 and P/B of 13.93. The current ratio is 3.14 and quick ratio is 2.70. Operationally, the company’s inventory turnover is 0.72 and cash conversion cycle is 438.01 days. Debt-to-equity is 1.31, supported by a cash flow-to-debt ratio of 0.09.
Quarterly Financial Highlights
The company ended the quarter with $352.30M in cash and short-term investments, a total debt of $110.93M, and net debt of - $241.37M. Total assets were $788.73M, with equity of $194.52M. Financials further reflected weakness, with operating cash flow of - $594.74M, free cash flow of - $595.51M, and capital expenditures of - $773.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that Apellis Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.1%, with price expected at $45.85 by May 01, 2026, within a range of $37.49 to $54.55 3-Month Outlook: Projected fall of -8.19%, reaching $37.55 by July 16, 2026, with a range of $35.38 to $39.29. 1-Year Outlook: Projected loss of -65.48%, with price at $14.12 by April 16, 2027, within a range of $10.52 to $18.98.
Key Takeaways
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are down -18.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Apellis Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 230.23. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $58.67, suggesting 43.45% upside. Our AI forecast model points to short-term strength (12.1% over two weeks), a medium-term fall (-8.19% over three months), and a longer-term loss (-65.48% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Apellis Pharmaceuticals, Inc. (APLS) stock price?
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock price is $40.88 in the last trading session. During the trading session, APLS stock reached the peak price of $40.90 while $40.88 was the lowest point it dropped to. The percentage change in APLS stock occurred in the recent session was -0.06% while the dollar amount for the price change in APLS stock was - $0.03.
APLS's industry and sector of operation?
The NASDAQ listed APLS is part of Biotechnology industry that operates in the broader Healthcare sector. Apellis Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of APLS?
Dr. Federico Grossi M.D., Ph.D.
Co-Founder & Chief Medical Officer
Mr. Timothy E. Sullivan
Chief Financial Officer & Treasurer
Dr. Pascal Deschatelets Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Alec Machiels J.D., MBA
Co-Founder & Director
Ms. Meredith Kaya
Senior Vice President, Investor Relations & Strategic Fin.
Mr. James G. Chopas CPA
Vice President, Corporation Controller & Chief Accounting Officer
Mr. David O. Watson Esq., J.D.
Gen. Counsel
Ms. Nur Nicholson
Chief Technical Operations Officer
Mr. Adam J. Townsend
Chief Commercial Officer
Ms. Karen Lewis
Chief People Officer
Dr. Cedric Francois M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Co-Founder & Chief Medical Officer
Mr. Timothy E. Sullivan
Chief Financial Officer & Treasurer
Dr. Pascal Deschatelets Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Alec Machiels J.D., MBA
Co-Founder & Director
Ms. Meredith Kaya
Senior Vice President, Investor Relations & Strategic Fin.
Mr. James G. Chopas CPA
Vice President, Corporation Controller & Chief Accounting Officer
Mr. David O. Watson Esq., J.D.
Gen. Counsel
Ms. Nur Nicholson
Chief Technical Operations Officer
Mr. Adam J. Townsend
Chief Commercial Officer
Ms. Karen Lewis
Chief People Officer
Dr. Cedric Francois M.D., Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
How APLS did perform over past 52-week?
APLS's closing price is 154.04% higher than its 52-week low of $16.10 where as its distance from 52-week high of $40.95 is -0.12%.
How many employees does APLS have?
Number of APLS employees currently stands at 705.
Link for APLS official website?
Official Website of APLS is: https://www.apellis.com
How do I contact APLS?
APLS could be contacted at phone 617 977 5700 and can also be accessed through its website. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, United States.
How many shares of APLS are traded daily?
APLS stock volume for the day was 173.19K shares. The average number of APLS shares traded daily for last 3 months was 5.31M.
What is the market cap of APLS currently?
The market value of APLS currently stands at $5.23B with its latest stock price at $40.88 and 127.83M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep